Cancer Genetic Testing for the Generalist Ob-Gyn: Beyond BRCA 1/2 - SC07

Friday, May 19, 2023

2:15 PM – 3:15 PM ET

Location: Ballroom III

CME Credits 1

Sub Topic: Office Management - Medical Problems

Jeffrey Dungan, MD (he/him/his)

Professor
Northwestern University Feinberg School of Medicine
Northwestern University Feinberg School of Medicine
Chicago, IL, United States

Disclosure(s): No financial relationships to disclose
TS

Theresa L. Sciaraffa-Aparicio, MA, MS (she/her/hers)

Cancer Genetic Counselor
Northwestern Medicine
Northwestern University Feinberg School of Medicine
Chicago, IL, United States

Disclosure(s): No financial relationships to disclose
Lee P. Shulman, MD

Professor of Obstetrics and Gynecology
Northwestern Medicine
Feinberg School of Medicine of Northwestern University
Northbrook, IL, United States

Disclosure(s): Agile: Consultant (Ongoing), Speaker/Honoraria (Ongoing); Alliancepharma: Consultant (Ongoing); American regent: Consultant (Terminated, February 1, 2022), Speaker/Honoraria (Terminated, February 1, 2022); Aspira: Consultant (Ongoing), Speaker/Honoraria (Ongoing); BD: Advisory Committee/Board Member (Ongoing); Celula China: Consultant (Ongoing); Scynexis: Advisory Committee/Board Member (Ongoing), Speaker/Honoraria (Ongoing)

Session Description
This panel session will highlight the essential points that health care professionals and patients need to know about interpreting cancer-related genetic testing results beyond BRCA1 and BRCA2. What should you tell your patient who shows up with a relative's genetic testing report? This interactive session will allow audience members to compare their management strategies with a group of cancer geneticists.

Disclosure(s):

Jeffrey Dungan, MD: No financial relationships to disclose

Theresa L. Sciaraffa-Aparicio, MS: No financial relationships to disclose

Lee P. Shulman, MD: Agile: Consultant (Ongoing), Speaker/Honoraria (Ongoing); Alliancepharma: Consultant (Ongoing); American regent: Consultant (Terminated, February 1, 2022), Speaker/Honoraria (Terminated, February 1, 2022); Aspira: Consultant (Ongoing), Speaker/Honoraria (Ongoing); BD: Advisory Committee/Board Member (Ongoing); Celula China: Consultant (Ongoing); Scynexis: Advisory Committee/Board Member (Ongoing), Speaker/Honoraria (Ongoing)